The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31 to June 4 in Chicago, will feature updates from Chinese pharmaceutical companies Ascentage Pharma (HKG: 6855), Lepu Biotechnology Co., Ltd (HKG: 2157), Transcenta Holding Ltd, and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) on their investigational drugs.
Ascentage:
- Updated efficacy data for olverembatinib in TKI-resistant SDH- gastrointestinal stromal tumors (GIST) and paragangliomas show a 92.3% clinical benefit rate with a consistent safety profile.
- Phase Ib/II study of Bcl-2 inhibitor APG-2575 combined with azacitidine in AML reports a 76.7% overall response rate and a 50.0% composite complete response rate.
- Phase Ib/II study of lisaftoclax alone or with ibrutinib or rituximab in Waldenström macroglobulinemia (WM) shows promising response rates.
- Latest data for FAK/ALK/ROS1 inhibitor APG-2449 in NSCLC resistant to second-generation ALK inhibitors indicate an ORR of 68.2% to 78.6%.
Lepu Bio:
- Phase I/II study of anti-tissue factor ADC MRG004A in solid tumors demonstrates significant antitumor activities in pancreatic cancer and triple negative breast cancer.
- Phase I/II study of pucotenlimab combined with EGFR-ADC MRG003 in EGFR+ solid tumors shows an ORR of 63.0% and a DCR of 88.9%.
- Exploratory biomarker analysis of CHANGEABLE study for HX008 combined with niraparib in metastatic breast cancer with germline mutation reports an ORR of 78.6%.
Transcenta:
Phase I/IIa study data for CLDN 18.2 monoclonal antibody osemitamab combined with nivolumab plus CAPOX as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma shows a significant therapeutic advantage with a mPFS of 12.6 months.
Kelun-Biotech:
- Phase III OptiTROP-Breast01 study of TROP2-targeted ADC sacituzumab tirumotecan in previously treated local recurrent or metastatic TNBC shows superior efficacy compared to chemotherapy.
- Phase II OptiTROP-Lung01 study of sacituzumab tirumotecan combined with PD-L1 mAb KL-A167 in first-line advanced NSCLC demonstrates high ORR and DCR rates.- Flcube.com
